Nothing Special   »   [go: up one dir, main page]

EA201990189A1 - Синтез n-(гетероарил)пирроло[3,2-d]пиримидин-2-аминов - Google Patents

Синтез n-(гетероарил)пирроло[3,2-d]пиримидин-2-аминов

Info

Publication number
EA201990189A1
EA201990189A1 EA201990189A EA201990189A EA201990189A1 EA 201990189 A1 EA201990189 A1 EA 201990189A1 EA 201990189 A EA201990189 A EA 201990189A EA 201990189 A EA201990189 A EA 201990189A EA 201990189 A1 EA201990189 A1 EA 201990189A1
Authority
EA
Eurasian Patent Office
Prior art keywords
synthesis
pyrrolo
pyrimidin
heteroaryl
amines
Prior art date
Application number
EA201990189A
Other languages
English (en)
Inventor
Александр Смит
Ханна С. Уайт
Франсис Ксавьер Таварес
Сергий Красутский
Цзянь-Се Чэнь
Роберта Л. Дорроу
Хуа Чжон
Original Assignee
Г1 Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Г1 Терапьютикс, Инк. filed Critical Г1 Терапьютикс, Инк.
Publication of EA201990189A1 publication Critical patent/EA201990189A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Изобретение относится к области синтеза соединений на основе пиримидина, применимых для лечения нарушений, характеризующихся аномальной клеточной пролиферацией, включая, но без ограничения, опухоли и различные виды рака.
EA201990189A 2016-07-01 2017-06-29 Синтез n-(гетероарил)пирроло[3,2-d]пиримидин-2-аминов EA201990189A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662357797P 2016-07-01 2016-07-01
PCT/US2017/040102 WO2018005865A1 (en) 2016-07-01 2017-06-29 Synthesis of n-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-amines

Publications (1)

Publication Number Publication Date
EA201990189A1 true EA201990189A1 (ru) 2019-06-28

Family

ID=60786476

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990189A EA201990189A1 (ru) 2016-07-01 2017-06-29 Синтез n-(гетероарил)пирроло[3,2-d]пиримидин-2-аминов

Country Status (13)

Country Link
US (2) US10865210B2 (ru)
EP (1) EP3478295A4 (ru)
JP (1) JP7106462B2 (ru)
KR (1) KR102445288B1 (ru)
CN (1) CN109789142B (ru)
AU (2) AU2017290362B2 (ru)
CA (1) CA3028752A1 (ru)
EA (1) EA201990189A1 (ru)
IL (1) IL263911B (ru)
MX (1) MX2019000199A (ru)
NZ (1) NZ749275A (ru)
WO (1) WO2018005865A1 (ru)
ZA (1) ZA201808535B (ru)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9487530B2 (en) * 2013-03-15 2016-11-08 G1 Therapeutics, Inc. Transient protection of normal cells during chemotherapy
WO2018005863A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
KR102576011B1 (ko) 2017-01-06 2023-09-06 쥐원 쎄라퓨틱스, 인크. 암의 치료를 위한 조합 요법
SG11202000418XA (en) 2017-07-18 2020-02-27 Nuvation Bio Inc Heterocyclic compounds as adenosine antagonists
MX2020000693A (es) 2017-07-18 2020-07-29 Nuvation Bio Inc Compuestos de 1,8-naftiridinona, y usos de los mismos.
CN112334451A (zh) 2018-02-15 2021-02-05 诺维逊生物股份有限公司 作为激酶抑制剂的杂环化合物
CN108299317A (zh) * 2018-03-20 2018-07-20 爱斯特（成都）生物制药股份有限公司 1,4-二氮杂螺[5,5]十一烷盐酸盐的合成方法
AU2019253706A1 (en) * 2018-04-09 2020-11-26 G1 Therapeutics, Inc. Treatment of cancers having driving oncogenic mutations
CN108840814B (zh) * 2018-07-24 2021-09-24 南京药石科技股份有限公司 一种8-氧代-2,6,9-三氮杂螺[4.5]癸烷-2-羧酸叔丁酯制备方法
CN112839657A (zh) * 2018-08-24 2021-05-25 G1治疗公司 1,4-二氮杂螺[5.5]十一烷-3-酮改进的合成
JP2022517419A (ja) 2019-01-18 2022-03-08 ニューベイション・バイオ・インコーポレイテッド アデノシンアンタゴニストとしてのヘテロ環式化合物
CA3126931A1 (en) 2019-01-18 2020-07-23 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
KR20230012547A (ko) 2020-05-19 2023-01-26 쥐원 쎄라퓨틱스, 인크. 의학적 장애의 치료를 위한 시클린-의존성 키나제 억제 화합물
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
TW202214650A (zh) * 2020-06-15 2022-04-16 美商G1治療公司 曲拉西利(trilaciclib)之型態形式及製造方法
EP4225758A1 (en) 2020-10-08 2023-08-16 Teva Pharmaceuticals International GmbH Solid state forms of trilaciclib and of trilaciclib salts
CN113788837B (zh) * 2021-08-02 2022-08-26 深圳湾实验室坪山生物医药研发转化中心 Trilaciclib的合成方法
CN113754600A (zh) * 2021-11-10 2021-12-07 天津敬康生物科技有限公司 1,4-二氮杂螺[5,5]十一烷-3-酮的制备方法
CN114014864B (zh) * 2021-12-21 2022-11-25 武汉九州钰民医药科技有限公司 一种曲拉西利化合物的制备工艺
CN114014863B (zh) * 2021-12-21 2022-11-29 武汉九州钰民医药科技有限公司 骨髓保护剂曲拉西利的制备方法
EP4486458A1 (en) * 2022-02-28 2025-01-08 Teva Pharmaceuticals International GmbH Crystalline forms of trilaciclib and trilaciclib salts
US11970403B2 (en) * 2022-06-27 2024-04-30 Saudi Arabian Oil Company Method of zeolite synthesis including pH-modified water-soluble oxidized disulfide oil composition
US11958751B2 (en) * 2022-06-27 2024-04-16 Saudi Arabian Oil Company Method of synthesizing materials integrating supernatant recycle
CN115477653B (zh) * 2022-10-11 2024-04-09 安徽省庆云医药股份有限公司 一种曲拉西利关键中间体及曲拉西利的制备方法
WO2024116069A1 (en) 2022-11-28 2024-06-06 Assia Chemical Industries Ltd. Novel trilaciclib intermediates, method of preparation and use thereof
TWI842274B (zh) * 2022-12-15 2024-05-11 中化合成生技股份有限公司 曲拉西利之製備方法及曲拉西利之前驅體
WO2024241152A1 (en) * 2023-05-19 2024-11-28 Olon S.P.A. Solvated form of trilaciclib dihydrochloride
WO2024246723A1 (en) * 2023-05-29 2024-12-05 Olon S.P.A. Solvated form of trilaciclib dihydrochloride

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506760B1 (en) * 2000-04-14 2003-01-14 Corvas International, Inc. Substituted hydrazinyl heteroaromatic inhibitors of thrombin
EP1307450B1 (en) * 2000-08-04 2008-09-17 Warner-Lambert Company LLC 2-(4-Pyridyl)amino-6-dialkoxyphenyl-pyrido(2,3-d)pyrimidin-7-ones
CA2498566A1 (en) * 2002-09-11 2004-06-10 Merck & Co., Inc. 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine compounds useful as hiv integrase inhibitors
WO2004065378A1 (en) * 2003-01-17 2004-08-05 Warner-Lambert Company Llc 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
JP4527732B2 (ja) 2004-01-08 2010-08-18 エフ．ホフマン−ラ ロシュ アーゲー グリシントランスポータ１およびグリシントランスポータ２の阻害物質としてのジアザスピロピペリジン誘導体
JP2008512460A (ja) 2004-09-08 2008-04-24 メルク エンド カムパニー インコーポレーテッド 単環式アニリドスピロラクタムｃｇｒｐ受容体拮抗薬
EP1793827B1 (en) 2004-09-09 2010-04-07 Merck Sharp & Dohme Corp. Tricyclic anilide spirolactam cgrp receptor antagonists
US7390798B2 (en) 2004-09-13 2008-06-24 Merck & Co., Inc. Carboxamide spirolactam CGRP receptor antagonists
JP2008512481A (ja) 2004-09-13 2008-04-24 メルク エンド カムパニー インコーポレーテッド 二環式アニリドスピロラクタムｃｇｒｐ受容体拮抗薬
US20060142312A1 (en) * 2004-12-23 2006-06-29 Pfizer Inc C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones
US7851464B2 (en) 2005-11-18 2010-12-14 Merck Sharp & Dohme Corp. Spirolactam aryl CGRP receptor antagonists
AU2007332898A1 (en) 2006-12-08 2008-06-19 Merck Sharp & Dohme Corp. Constrained spirocyclic compounds as CGRP receptor antagonists
WO2008109464A1 (en) 2007-03-02 2008-09-12 University Of Massachusetts Spirolactam targeting compounds and related compounds
EP2271629A1 (en) * 2008-04-22 2011-01-12 AstraZeneca AB Substituted pyrimidin-5-carboxamides 281
CN103788100A (zh) 2008-08-22 2014-05-14 诺华股份有限公司 作为cdk抑制剂的吡咯并嘧啶化合物
US8691830B2 (en) 2010-10-25 2014-04-08 G1 Therapeutics, Inc. CDK inhibitors
CN106008533B (zh) 2010-10-25 2018-01-23 G1治疗公司 Cdk抑制剂
US8829102B2 (en) 2010-10-27 2014-09-09 Cabot Corporation High loading carbon black masterbatch for pressure pipe applications
EP3216792B1 (en) 2012-03-29 2020-05-27 G1 Therapeutics, Inc. Lactam kinase inhibitors
EP2841417A1 (en) 2012-04-26 2015-03-04 Francis Xavier Tavares Synthesis of lactams
EP2846798B1 (en) 2012-05-09 2018-04-04 Merck Sharp & Dohme Corp. Aliphatic spirolactam cgrp receptor antagonists
JP6435315B2 (ja) * 2013-03-15 2018-12-05 ジー１、セラピューティクス、インコーポレイテッドＧ１ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 高活性抗新生物薬及び抗増殖剤
WO2014144596A2 (en) 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Transient protection of hematopoietic stem and progenitor cells against ionizing radiation
US9487530B2 (en) 2013-03-15 2016-11-08 G1 Therapeutics, Inc. Transient protection of normal cells during chemotherapy
US20160287592A1 (en) 2013-04-08 2016-10-06 Pharmacyclics Llc Ibrutinib combination therapy
US20150031674A1 (en) * 2013-07-26 2015-01-29 Genentech, Inc. Serine/threonine kinase inhibitors
WO2015061407A1 (en) 2013-10-24 2015-04-30 Francis Xavier Tavares Process for synthesis of lactams
US9481591B1 (en) 2013-12-16 2016-11-01 Barbara Blake Device and process to treat and disinfect sewage, food processing wastewater and other biologically contaminated water
WO2015161287A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic lactams for use in the protection of normal cells during chemotherapy
WO2016040858A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
CN105622638B (zh) * 2014-10-29 2018-10-02 广州必贝特医药技术有限公司 嘧啶或吡啶并吡啶酮类化合物及其制备方法和应用
KR20190097242A (ko) 2017-01-23 2019-08-20 화이자 인코포레이티드 Magl 억제제로서의 헤테로시클릭 스피로 화합물

Also Published As

Publication number Publication date
US11629150B2 (en) 2023-04-18
US20190135820A1 (en) 2019-05-09
WO2018005865A1 (en) 2018-01-04
BR112018077155A2 (pt) 2019-04-02
AU2021261879A1 (en) 2021-12-02
RU2019102643A3 (ru) 2020-08-21
AU2017290362B2 (en) 2021-08-05
CN109789142B (zh) 2022-08-23
KR20190025651A (ko) 2019-03-11
CA3028752A1 (en) 2018-01-04
AU2021261879B2 (en) 2024-01-04
NZ749275A (en) 2023-06-30
US10865210B2 (en) 2020-12-15
ZA201808535B (en) 2024-08-28
EP3478295A1 (en) 2019-05-08
KR102445288B1 (ko) 2022-09-19
AU2017290362A1 (en) 2019-01-17
CN109789142A (zh) 2019-05-21
EP3478295A4 (en) 2019-12-04
RU2019102643A (ru) 2020-08-03
US20210122755A1 (en) 2021-04-29
IL263911A (en) 2019-01-31
MX2019000199A (es) 2019-09-23
IL263911B (en) 2021-10-31
JP2019520380A (ja) 2019-07-18
JP7106462B2 (ja) 2022-07-26

Similar Documents

Publication Publication Date Title
EA201990189A1 (ru) Синтез n-(гетероарил)пирроло[3,2-d]пиримидин-2-аминов
EA201990187A1 (ru) Антипролиферационные средства на основе пиримидина
PH12018502710A1 (en) Heterocyclic compounds as immunomodulators
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
EA201891494A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
PH12018500587A1 (en) Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer
EA201792529A1 (ru) Ингибиторы тирозинкиназы
NZ735998A (en) Heterocyclic compounds as lsd1 inhibitors
TR201819138T4 (tr) FGFR Kinaz Modülatörleri Olarak Faydalı Kinoksalin Türevleri
EA201791507A1 (ru) Пирроло- и пиразолопиримидины в качестве ингибиторов убиквитин- специфичной протеазы 7
EA201890125A1 (ru) Новые гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их
PH12016501107A1 (en) Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
WO2016130920A3 (en) Lrrk2 inhibitors and methods of making and using the same
EA201591823A1 (ru) Ингибиторы ido
EA201690316A1 (ru) Соединения для применения в качестве иммуномодуляторов
EA201591753A1 (ru) 3-пиримидин-4-илоксазолидин-2-оны в качестве ингибиторов мутантного idh
EA201070618A1 (ru) 4-пиразолил-n-арилпиримидин-2-амины и 4-пиразолил-n-гетероарилпиримидин-2-амины в качестве ингибиторов киназ janus
EA201891526A3 (ru) Ингибиторы лизин-специфической деметилазы-1
EA201790082A1 (ru) Ингибиторы лизин-специфической демитилазы-1
EA201990400A1 (ru) Соединения и композиции и их применение
EA202090414A1 (ru) Соединения и их применение
EA201992302A1 (ru) Соединения, используемые в качестве ингибиторов alcat1
EA201990399A1 (ru) Соединения, композиции и их применение
EA202091691A1 (ru) ТВЕРДЫЕ ФОРМЫ ЗАМЕЩЕННЫХ 5,6-ДИГИДРО-6-ФЕНИЛБЕНЗО[f]ИЗОХИНОЛИН-2-АМИНОВЫХ СОЕДИНЕНИЙ